[go: up one dir, main page]

WO2017151940A3 - T-cell modulatory multimeric polypeptides and methods of use thereof - Google Patents

T-cell modulatory multimeric polypeptides and methods of use thereof Download PDF

Info

Publication number
WO2017151940A3
WO2017151940A3 PCT/US2017/020480 US2017020480W WO2017151940A3 WO 2017151940 A3 WO2017151940 A3 WO 2017151940A3 US 2017020480 W US2017020480 W US 2017020480W WO 2017151940 A3 WO2017151940 A3 WO 2017151940A3
Authority
WO
WIPO (PCT)
Prior art keywords
present disclosure
modulatory multimeric
cell
polypeptides
cell modulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/020480
Other languages
French (fr)
Other versions
WO2017151940A2 (en
Inventor
III Ronald D. SEIDEL
Rodolfo CHAPARRO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cue Biopharma Inc
Original Assignee
Cue Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA3014466A priority Critical patent/CA3014466A1/en
Priority to US16/077,303 priority patent/US20190046648A1/en
Priority to KR1020187028429A priority patent/KR20180132070A/en
Priority to EP17760833.8A priority patent/EP3423078A4/en
Priority to AU2017225787A priority patent/AU2017225787B2/en
Priority to JP2018546577A priority patent/JP7372036B2/en
Priority to CN201780027393.7A priority patent/CN109414498A/en
Application filed by Cue Biopharma Inc filed Critical Cue Biopharma Inc
Publication of WO2017151940A2 publication Critical patent/WO2017151940A2/en
Publication of WO2017151940A3 publication Critical patent/WO2017151940A3/en
Priority to IL261402A priority patent/IL261402A/en
Anticipated expiration legal-status Critical
Priority to US17/958,904 priority patent/US20230330235A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)

Abstract

The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.
PCT/US2017/020480 2016-03-03 2017-03-02 T-cell modulatory multimeric polypeptides and methods of use thereof Ceased WO2017151940A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US16/077,303 US20190046648A1 (en) 2016-03-03 2017-03-02 T-cell modulatory multimeric polypeptides and methods of use thereof
KR1020187028429A KR20180132070A (en) 2016-03-03 2017-03-02 T-cell modulated multimeric polypeptides and methods for their use
EP17760833.8A EP3423078A4 (en) 2016-03-03 2017-03-02 T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE
AU2017225787A AU2017225787B2 (en) 2016-03-03 2017-03-02 T-cell modulatory multimeric polypeptides and methods of use thereof
JP2018546577A JP7372036B2 (en) 2016-03-03 2017-03-02 T cell regulatory multimeric polypeptides and methods of use thereof
CA3014466A CA3014466A1 (en) 2016-03-03 2017-03-02 T-cell modulatory multimeric polypeptides and methods of use thereof
CN201780027393.7A CN109414498A (en) 2016-03-03 2017-03-02 T cell modulability multimeric polypeptide and its application method
IL261402A IL261402A (en) 2016-03-03 2018-08-27 T-cell modulatory multimeric polypeptides and methods of use thereof
US17/958,904 US20230330235A1 (en) 2016-03-03 2022-10-03 T-cell modulatory multimeric polypeptides and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662303268P 2016-03-03 2016-03-03
US62/303,268 2016-03-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/077,303 A-371-Of-International US20190046648A1 (en) 2016-03-03 2017-03-02 T-cell modulatory multimeric polypeptides and methods of use thereof
US17/958,904 Continuation US20230330235A1 (en) 2016-03-03 2022-10-03 T-cell modulatory multimeric polypeptides and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2017151940A2 WO2017151940A2 (en) 2017-09-08
WO2017151940A3 true WO2017151940A3 (en) 2017-10-12

Family

ID=59743280

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/020480 Ceased WO2017151940A2 (en) 2016-03-03 2017-03-02 T-cell modulatory multimeric polypeptides and methods of use thereof

Country Status (9)

Country Link
US (2) US20190046648A1 (en)
EP (1) EP3423078A4 (en)
JP (1) JP7372036B2 (en)
KR (1) KR20180132070A (en)
CN (1) CN109414498A (en)
AU (1) AU2017225787B2 (en)
CA (1) CA3014466A1 (en)
IL (1) IL261402A (en)
WO (1) WO2017151940A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015013557B1 (en) 2012-12-11 2021-12-14 Albert Einstein College Of Medicine SYSTEM, METHOD, METHOD FOR DETERMINING THE EFFECT OF A PREDETERMINED AMINO ACID RESIDUE OF A FIRST PROTEIN ON BINDING OF THE FIRST PROTEIN TO A SECOND PROTEIN AND MUTANT PD-L1 POLYPEPTIDE
CN109689096A (en) 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 Variant PD-L1 polypeptides, T cell regulatory multimer polypeptides, and methods of using the same
KR20190019068A (en) * 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-cell modulated multimeric polypeptides and methods for their use
PT3558339T (en) 2016-12-22 2024-03-15 Cue Biopharma Inc MULTIMER POLYPEPTIDES THAT MODULATE T CELLS AND METHODS OF USE THEREOF
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3054955A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
SG11201910101SA (en) 2017-05-08 2019-11-28 Gritstone Oncology Inc Alphavirus neoantigen vectors
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. ANTI-CD137 MOLECULES AND THEIR USE
CA3074839A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
EP3737689A4 (en) * 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019226939A1 (en) * 2018-05-23 2019-11-28 Gritstone Oncology, Inc. Immune checkpoint inhibitor co-expression vectors
JP7691927B2 (en) * 2019-03-06 2025-06-12 キュー バイオファーマ， インコーポレイテッド T cell modulating antigen presenting polypeptides and methods of use thereof
MX2021014476A (en) * 2019-05-29 2022-02-11 Cue Biopharma Inc T-LYMPHOCYTE MODULATOR MULTIMER POLYPEPTIDES AND METHODS OF USE OF THEM.
CN114072516B (en) 2019-05-30 2025-01-14 磨石生物公司 Modified adenovirus
JP2022535538A (en) * 2019-06-05 2022-08-09 アダジーン プライベート リミテッド Anti-CD137L Antibodies and Methods of Using Them
WO2020257191A1 (en) * 2019-06-19 2020-12-24 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
KR20220066075A (en) * 2019-09-20 2022-05-23 큐 바이오파마, 인크. T-cell regulatory polypeptides and methods of use thereof
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2023541108A (en) 2020-08-06 2023-09-28 グリットストーン バイオ インコーポレイテッド Multi-epitope vaccine cassette
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
JP2023541366A (en) * 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド MHC class II T cell modulating multimeric polypeptides and methods of use thereof to treat type 1 diabetes mellitus (T1D)
MX2023008966A (en) * 2021-02-07 2023-09-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Bispecific antibody.
EP4608855A1 (en) * 2022-10-28 2025-09-03 FBD Biologics Limited Engineered 4-1bbl variants and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038349A1 (en) * 2001-07-27 2004-02-26 Hilbert David M. Heteromultimeric TNF ligand family members
US20040209363A1 (en) * 2001-07-12 2004-10-21 Tania Watts Methods and compositions for modulating T cell activation and uses thereof
WO2015195531A2 (en) * 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (en) 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
JPH08503855A (en) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション Gene therapy for cystic fibrosis
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
JP3875990B2 (en) 1993-10-25 2007-01-31 カンジ，インコーポレイテッド Recombinant adenoviral vectors and methods of use
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
ATE321855T1 (en) * 1997-01-14 2006-04-15 Human Genome Sciences Inc TUMOR NECROSIS FACTOR RECEPTOR 5
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
AU2002366433A1 (en) * 2001-08-16 2003-09-09 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US6911321B2 (en) * 2001-12-19 2005-06-28 Genentech, Inc. Non-human primate Fc receptors and methods of use
US8895020B2 (en) * 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
ES2601327T3 (en) * 2006-01-23 2017-02-14 Novozymes A/S Polypeptides with lipase activity and polynucleotides encoding them
EP2361930A3 (en) * 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
CN102898504B (en) * 2012-10-23 2014-08-06 中国农业大学 Antioxidation active synthetic peptide and purpose thereof
AU2014291961B2 (en) * 2013-07-19 2018-09-27 Centre Hospitalier Regional Universitaire De Montpellier Targeted modified TNF family members
US11111284B2 (en) * 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
KR20190019068A (en) * 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-cell modulated multimeric polypeptides and methods for their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040209363A1 (en) * 2001-07-12 2004-10-21 Tania Watts Methods and compositions for modulating T cell activation and uses thereof
US20040038349A1 (en) * 2001-07-27 2004-02-26 Hilbert David M. Heteromultimeric TNF ligand family members
WO2015195531A2 (en) * 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof

Also Published As

Publication number Publication date
JP2019512222A (en) 2019-05-16
AU2017225787A1 (en) 2018-08-30
KR20180132070A (en) 2018-12-11
CA3014466A1 (en) 2017-09-08
IL261402A (en) 2018-10-31
EP3423078A4 (en) 2019-11-06
EP3423078A2 (en) 2019-01-09
US20230330235A1 (en) 2023-10-19
JP7372036B2 (en) 2023-10-31
WO2017151940A2 (en) 2017-09-08
AU2017225787B2 (en) 2021-09-23
US20190046648A1 (en) 2019-02-14
CN109414498A (en) 2019-03-01

Similar Documents

Publication Publication Date Title
WO2017151818A3 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
WO2017151940A3 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
PH12019501413A1 (en) T-cell modulatory multimeric polypeptides and method of use thereof
AU2017266905A1 (en) Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
EP4600372A3 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2023007211A (en) Anti-myostatin antibodies and methods of use.
MX395455B (en) Binding-activated transcriptional switches and methods for their use
EP4219702A3 (en) Enzyme variants and polynucleotides encoding the same
BR112018073606A2 (en) T-cell modulating multimeric polypeptides and methods of using them
EP4389139A3 (en) Factor viii chimeric proteins and uses thereof
MX2021000047A (en) Pd1-4-1bbl variant fusion protein and methods of use thereof.
MX2021000263A (en) SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF.
WO2015140638A8 (en) Glycosylated vegf decoy receptor fusion protein
WO2016130628A8 (en) Griffithsin mutants
AU2021214163A1 (en) Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
WO2016036635A8 (en) Chromobacterium subtsugae genes
WO2014152247A8 (en) Improved tnf binding proteins
WO2015120542A8 (en) Hybrid proteins and uses thereof
WO2015077506A3 (en) Identification of a novel b cell cytokine
WO2016160976A3 (en) Monovalent tnf binding proteins
WO2017204561A3 (en) Recombinant polynucleotide coding for polypeptide comprising reporter moiety, substrate moiety and destabilizing moiety, host cell comprising same and use of same
ZA202104520B (en) Recombinant human 2ig-b7-h3 protein coding gene, recombinant vector, host cell comprising the same, pharmaceutical composition and use thereof
EA201991195A1 (en) MULTI-DIMENSIONAL POLYPEPTIDES MODULATING T-CELLS AND WAYS OF THEIR APPLICATION
WO2019147623A3 (en) Mda-7/il secretory variants and methods of use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 3014466

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 261402

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2017225787

Country of ref document: AU

Date of ref document: 20170302

Kind code of ref document: A

Ref document number: 2018546577

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20187028429

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017760833

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017760833

Country of ref document: EP

Effective date: 20181004

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17760833

Country of ref document: EP

Kind code of ref document: A2